Hui Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hui Yuan has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Peter Edward Lobie
Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China
71 shared publications - Tao Zhu
Shenzhen Bay Laboratory, Shenzhen, PR China
71 shared publications - Mingming Wu
Department of Biological and Environmental Engineering, Cornell University
70 shared publications - Xiao Zhang
Department of Oncology, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
70 shared publications - Huafeng Zhang
Department of Orthopedics, Tianjin Medical University General Hospital, Tianjin, China
65 shared publications - Linlin Yan
Translational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, China
65 shared publications
Latest Publications
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Table S2 Lists antibodies used in western blot, immunofluorescence and Flow cytometry.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Table S2 Lists antibodies used in western blot, immunofluorescence and Flow cytometry.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Supplementary Figure S2 shows that BCSC CM enhances the aerobic glycolysis not oxidative phosphorylation.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Supplementary Figure S2 shows that BCSC CM enhances the aerobic glycolysis not oxidative phosphorylation.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Table S1 shows the sequences of sgRNAs, shRNAs and primers for cloning and qRT-PCR analysis.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Table S1 shows the sequences of sgRNAs, shRNAs and primers for cloning and qRT-PCR analysis.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Table S2 Lists antibodies used in western blot, immunofluorescence and Flow cytometry.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Table S2 Lists antibodies used in western blot, immunofluorescence and Flow cytometry.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Data from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Reprogramming of energy metabolism exerts pivotal functions in cancer progression and immune surveillance. Identification of the mechanisms mediating metabolic changes in cancer may lead to improved strategies to suppress tumor growth and stimulate antitumor immunity. Here, it was observed that the secretomes of hypoxic breast cancer cells and breast cancer stem cells (BCSC) induced reprogramming of metabolic pathways, particularly glycolysis, in normoxic breast cancer cells. Screening of the BCSC secretome identified MIF as a pivotal factor potentiating glycolysis. Mechanistically, MIF increased c-MYC–mediated transcriptional upregulation of the glycolytic enzyme aldolase C by activating WNT/β-catenin signaling. Targeting MIF attenuated glycolysis and impaired xenograft growth and metastasis. MIF depletion in breast cancer cells also augmented intratumoral cytolytic CD8+ T cells and proinflammatory macrophages while decreasing regulatory T cells and tumor-associated neutrophils in the tumor microenvironment. Consequently, targeting MIF improved the therapeutic efficacy of immune checkpoint blockade in triple-negative breast cancer. Collectively, this study proposes MIF as an attractive therapeutic target to circumvent metabolic reprogramming and immunosuppression in breast cancer.Significance:MIF secreted by breast cancer stem cells induces metabolic reprogramming in bulk tumor cells and engenders an immunosuppressive microenvironment, identifying MIF targeting as a strategy to improve immunotherapy efficacy in breast cancer.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Reprogramming of energy metabolism exerts pivotal functions in cancer progression and immune surveillance. Identification of the mechanisms mediating metabolic changes in cancer may lead to improved strategies to suppress tumor growth and stimulate antitumor immunity. Here, it was observed that the secretomes of hypoxic breast cancer cells and breast cancer stem cells (BCSC) induced reprogramming of metabolic pathways, particularly glycolysis, in normoxic breast cancer cells. Screening of the BCSC secretome identified MIF as a pivotal factor potentiating glycolysis. Mechanistically, MIF increased c-MYC–mediated transcriptional upregulation of the glycolytic enzyme aldolase C by activating WNT/β-catenin signaling. Targeting MIF attenuated glycolysis and impaired xenograft growth and metastasis. MIF depletion in breast cancer cells also augmented intratumoral cytolytic CD8+ T cells and proinflammatory macrophages while decreasing regulatory T cells and tumor-associated neutrophils in the tumor microenvironment. Consequently, targeting MIF improved the therapeutic efficacy of immune checkpoint blockade in triple-negative breast cancer. Collectively, this study proposes MIF as an attractive therapeutic target to circumvent metabolic reprogramming and immunosuppression in breast cancer.Significance:MIF secreted by breast cancer stem cells induces metabolic reprogramming in bulk tumor cells and engenders an immunosuppressive microenvironment, identifying MIF targeting as a strategy to improve immunotherapy efficacy in breast cancer.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Table S1 shows the sequences of sgRNAs, shRNAs and primers for cloning and qRT-PCR analysis.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Table S1 shows the sequences of sgRNAs, shRNAs and primers for cloning and qRT-PCR analysis.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Supplementary Figure S3 shows that MIF is identified as a key cytokine secreted by BCSC.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Supplementary Figure S3 shows that MIF is identified as a key cytokine secreted by BCSC.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Supplementary Figure S8 shows that Targeting MIF enhances cancer cell sensitivity to immune cell killing.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Supplementary Figure S8 shows that Targeting MIF enhances cancer cell sensitivity to immune cell killing.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Supplementary Figure S2 shows that BCSC CM enhances the aerobic glycolysis not oxidative phosphorylation.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Supplementary Figure S2 shows that BCSC CM enhances the aerobic glycolysis not oxidative phosphorylation.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Supplementary Figure S1 shows that CoCl2 CM enhances breast cancer glycolysis.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Supplementary Figure S1 shows that CoCl2 CM enhances breast cancer glycolysis.